Prognostic value of circulating microRNAs in upper tract urinary carcinoma

dc.contributor.author
Montalbo Calafell, Ruth
dc.contributor.author
Izquierdo Reyes, Laura
dc.contributor.author
Ingelmo-Torres, Mercedes
dc.contributor.author
Lozano Salvatella, Juan José
dc.contributor.author
Capitán, David
dc.contributor.author
Alcaraz Asensio, Antonio
dc.contributor.author
Mengual Brichs, Lourdes
dc.date.issued
2019-04-03T16:48:58Z
dc.date.issued
2019-04-03T16:48:58Z
dc.date.issued
2018-03-30
dc.date.issued
2019-04-03T16:48:58Z
dc.identifier
1949-2553
dc.identifier
https://hdl.handle.net/2445/131304
dc.identifier
686134
dc.identifier
29682178
dc.description.abstract
The identification of upper tract urinary carcinoma (UTUC) prognostic biomarkers is urgently needed to predict tumour progression. This study aimed to identify serum microRNAs (miRNAs) that may be useful as minimally invasive predictive biomarkers of tumour progression and survival in UTUC patients. To this end, 33 UTUC patients who underwent radical nephroureterectomy at the Hospital Clinic of Barcelona were prospectively included. Expression of 800 miRNAs was evaluated in serum samples from these patients using nCounter® miRNA Expression Assays. The study was divided into an initial discovery phase (n=12) and a validation phase (n=21). Cox regression analysis was used for survival analysis. The median follow-up (range) of the series was 42 months (9-100 months). In the discovery phase, 38 differentially expressed miRNAs were identified between progressing and non-progressing UTUC patients (p<0.05). Validation of these 38 miRNAs in an independent set of UTUC patients confirmed the differential expression in 18 of them (p<0.05). Cox Regression analysis showed miR-151b and pathological stage as significant prognostic factors for tumour progression (HR=0.33, p<0.001 and HR=2.62, p=0.006, respectively) and cancer specific survival (HR=0.25, p<0.001 and HR=3.98, p=0.003, respectively). Survival curves revealed that miR-151b is able to discriminate between two groups of UTUC patients with a highly significant different probability of tumour progression (p=0.006) and cancer specific survival (p=0.034). Although the data needs to be externally validated, miRNA analysis in serum appears to be a valuable prognostic tool in UTUC patients. Particularly, differential expression of miR-151b in serum may serve as a minimally invasive prognostic tool in UTUC.
dc.format
10 p.
dc.format
application/pdf
dc.language
eng
dc.publisher
Impact Journals
dc.relation
Reproducció del document publicat a: https://doi.org/10.18632/oncotarget.24672
dc.relation
Oncotarget, 2018, vol. 9, num. 24, p. 16691-16700
dc.relation
https://doi.org/10.18632/oncotarget.24672
dc.rights
cc-by (c) Montalbo, Ruth et al., 2018
dc.rights
http://creativecommons.org/licenses/by/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)
dc.subject
Càncer de ronyó
dc.subject
Càncer
dc.subject
Marcadors tumorals
dc.subject
Renal cancer
dc.subject
Cancer
dc.subject
Tumor markers
dc.title
Prognostic value of circulating microRNAs in upper tract urinary carcinoma
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.